An Open-label, Randomized, Three-period, Crossover Study of the Effect of Food on the Pharmacokinetics of a Single Oral Dose of Sitravatinib in Healthy Adult Subjects
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
36
100 mg sitravatinib on Day 1 of each of 3 periods
Covance Clinical Research Unit, Inc.
Dallas, Texas, United States
Pharmacokinetics - Cmax (sitravatinib)
Maximum observed plasma concentration
Time frame: Up to 72 hours after dosing
Pharmacokinetics - AUC∞ (sitravatinib)
Area under the plasma concentration-time curve from time zero extrapolated to infinity
Time frame: Up to 72 hours after dosing
Pharmacokinetics - AUClast (sitravatinib)
AUC from time zero to the last measured time point
Time frame: Up to 72 hours after dosing
Adverse Events (AEs)
Incidence and severity of adverse events (AEs) dosed in the fasted and fed states in healthy adult subjects
Time frame: Up to 44 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.